High Flow Nasal Therapy-myAirvo 3 for COPD Patients (HiFloCOPD)

What is the HiFlo Study?

This study is for recently hospitalized patients (within 6 weeks of discharge). The myAirvo 3 is a device which delivers either air or oxygen via a special nasal cannula (called the Optiflow + Duet nasal canula) at high flow rates; the inhaled gas is warmed and humidified for comfort. The purpose of the study is to evaluate whether home use of myAirvo 3 in addition to your usual COPD medical care reduces the risk of COPD flare-ups and increases the time to rehospitalization.

airflow3
You might qualify for this study if you have:
  • Moderate to severe COPD as determined by lung function tests
  • Hospitalized with COPD flare-up in last 6 weeks
  • Using standard inhaler treatment when the flare up occurred
  • Current or former smokers

What Will My Role Be in the Study?

If you participate, you will be randomly assigned to either continue your usual medical care for COPD or use the myAirvo 3 high-flow nasal canula in addition to your usual COPD medical care  daily or at night for minimum of 8 hours. You will have up to 6 clinic visits and monthly telephone calls and will be followed for 1-2 years. You will be compensated $100 per clinic visit, and parking is provided. You will do questionnaires, lung function tests, blood work and a walk test.

Retirement age woman using inhaler for flu and cold treatment sitting on the sofa at home, senior older female cover face with an oxygen mask. Healthcare and medicine concept
Interested in a Research Study, Click Here For Our Registry Survey!
© 2024 Emphysema COPD Research Center

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!